JP2024523363A5 - - Google Patents
Info
- Publication number
- JP2024523363A5 JP2024523363A5 JP2023577658A JP2023577658A JP2024523363A5 JP 2024523363 A5 JP2024523363 A5 JP 2024523363A5 JP 2023577658 A JP2023577658 A JP 2023577658A JP 2023577658 A JP2023577658 A JP 2023577658A JP 2024523363 A5 JP2024523363 A5 JP 2024523363A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163212476P | 2021-06-18 | 2021-06-18 | |
| US63/212,476 | 2021-06-18 | ||
| PCT/US2022/033936 WO2022266415A1 (en) | 2021-06-18 | 2022-06-17 | Compounds and methods for reducing ifnar1 expression |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024523363A JP2024523363A (ja) | 2024-06-28 |
| JPWO2022266415A5 JPWO2022266415A5 (https=) | 2025-06-25 |
| JP2024523363A5 true JP2024523363A5 (https=) | 2025-06-25 |
Family
ID=84527458
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023577658A Pending JP2024523363A (ja) | 2021-06-18 | 2022-06-17 | Ｉｆｎａｒ１の発現を低減するための化合物及び方法 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20250188476A1 (https=) |
| EP (1) | EP4355338A4 (https=) |
| JP (1) | JP2024523363A (https=) |
| WO (1) | WO2022266415A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240023602A (ko) | 2021-06-18 | 2024-02-22 | 아이오니스 파마수티컬즈, 인코포레이티드 | Ifnar1 발현을 감소시키기 위한 화합물 및 방법 |
| KR20260005258A (ko) * | 2023-04-21 | 2026-01-09 | 세카나 파머씨티컬스 지엠비에이치 엔 씨오. 케이지 | Nrp1 특이적 안티센스 올리고뉴클레오티드 및 질병 예방 및/또는 치료에 있어서의 그 용도 |
| EP4724582A1 (en) * | 2023-06-07 | 2026-04-15 | Massachusetts Institute of Technology | Rna-loaded lipid nanoparticles |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0807172A1 (en) * | 1995-01-30 | 1997-11-19 | HYBRIDON, Inc. | Human immunodeficiency virus transcription inhibitors and methods of their use |
| WO2012068636A1 (en) * | 2010-11-26 | 2012-05-31 | The University Of Melbourne | Methods and compositions comprising antagonists of type 1 interferon-mediated signalling for reducing a neuroinflammatory response in the central nervous system |
| AU2014274730A1 (en) * | 2013-06-07 | 2016-01-21 | Rana Therapeutics, Inc. | Compositions and methods for modulating FOXP3 expression |
| US20200345756A1 (en) * | 2017-10-10 | 2020-11-05 | University Of Virginia Patent Foundation | Compositions and methods for treating age-related macular degeneration and geographic atrophy |
| EP3713955A4 (en) * | 2018-09-18 | 2022-03-09 | I-Mab Biopharma (Hangzhou) Co., Ltd. | ANTI-IFNAR1 ANTIBODIES FOR THE TREATMENT OF AUTOIMMUNE DISEASES |
| US20220064636A1 (en) * | 2018-10-05 | 2022-03-03 | Ionis Pharmaceuticals, Inc. | Modified oligomeric compounds and uses thereof |
-
2022
- 2022-06-17 JP JP2023577658A patent/JP2024523363A/ja active Pending
- 2022-06-17 WO PCT/US2022/033936 patent/WO2022266415A1/en not_active Ceased
- 2022-06-17 EP EP22825887.7A patent/EP4355338A4/en active Pending
- 2022-06-17 US US18/570,839 patent/US20250188476A1/en active Pending